Silverback Therapeutics to Participate in the Raymond James Human Health Innovation Conference

Rhea-AI Summary

Silverback Therapeutics, Inc. (Nasdaq: SBTX) is set to participate in the Raymond James Human Health Innovation Conference on June 23, 2021, at 3:20 PM ET. CEO Laura Shawver will present a corporate overview, with a live webcast available on the investor relations website. A replay will be accessible for 30 days. Silverback focuses on developing targeted therapeutics for cancer and serious diseases using its ImmunoTAC platform.

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the Raymond James Human Health Innovation Conference.

Laura Shawver, Ph.D., Silverback’s Chief Executive Officer, will provide a corporate overview on Wednesday, June 23^rd, 2021, at 3:20 PM ET / 12:20 PM PT. The live webcast of the presentation will be available on Silverback’s investor relations website and a replay will be available for 30 days following the event. Members of the Silverback management team will also host investor meetings during the conference.

About Silverback Therapeutics

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005053/en/

FAQ

When is Silverback Therapeutics presenting at the Raymond James Human Health Innovation Conference?

Silverback Therapeutics will present on June 23, 2021, at 3:20 PM ET.

Who will represent Silverback Therapeutics at the conference?

CEO Laura Shawver will provide the corporate overview during the conference.

Where can I watch the Silverback Therapeutics presentation live?

The live webcast will be available on Silverback's investor relations website.

What is Silverback Therapeutics' focus?

Silverback is focused on developing tissue-targeted therapeutics for cancer and serious diseases using its ImmunoTAC technology.

What type of technology does Silverback Therapeutics use?

Silverback Therapeutics utilizes its proprietary ImmunoTAC technology platform for its drug development.